Protein therapy for Unverricht-Lundborg disease using cystatin B transduction by TAT-PTD. Is it that simple?

Danielle M. Andrade, Stephen W. Scherer, Berge A. Minassian

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

In this work we analysed the characteristics of the cell-permeable peptide TAT-PTD fused to cystatin B (CSTB) to evaluate its potential for protein therapy of Unverricht-Lundborg (UL) epilepsy. TAT-PTD-CSTB does not penetrate the cells despite initial evidence of time and concentration-dependent transduction. Therefore, it cannot be used as a form of replacement of the intracytoplasmic protein missing in UL. Importantly, we discuss precautions to avoid false-positive results when working with TAT-PTD for protein therapy of neurological diseases.

Original languageEnglish (US)
Pages (from-to)75-79
Number of pages5
JournalEpilepsy Research
Volume72
Issue number1
DOIs
StatePublished - Nov 1 2006

Keywords

  • Blood-brain-barrier
  • Cell-permeable peptide
  • Progressive myoclonus epilepsy
  • Protein therapy
  • TAT-PTD
  • Unverrricht-Lundborg

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Protein therapy for Unverricht-Lundborg disease using cystatin B transduction by TAT-PTD. Is it that simple?'. Together they form a unique fingerprint.

  • Cite this